ArticleFunction (Oxford, England)2026
Persistent suppression of phrenic motor plasticity after mild acute systemic inflammation in adult rats.
Article in Function (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Inflammation, which is commonly associated with lung and neurological disorders, undermines a form of spinal serotonin-dependent respiratory motor plasticity elicited by moderate acute intermittent hypoxia (mAIH), known as phrenic long-term facilitation (pLTF). In adult rats, pLTF suppression has been studied 24 h following exposure to low-dose lipopolysaccharide (LPS) or 8 h of intermittent hypoxia simulating sleep apnea. In this timeframe, pLTF is suppressed by an adenosine 2 A (A2a) receptor and p38 MAP kinase-dependent mechanism. However, the duration of plasticity suppression following acute inflammation is unknown. We hypothesized that pLTF recovers when neuroinflammatory molecules return to normal. Thus, in Sprague Dawley rats, we assessed pLTF, ventral spinal (C3-C6) adenosine, and proinflammatory molecules after LPS (100 µg/kg ip). LPS increased spinal adenosine and microglial inflammatory genes at 24 h, but not 1 wk after LPS. Regardless, mAIH-induced pLTF remained suppressed for 3 wk, and then slowly recovered between 3 and 5 wk after LPS. Thus, pLTF suppression outlasts active inflammation. Contrary to 24 hours, at 1 wk after LPS, spinal A2a receptor inhibition (MSX-3) failed to restore pLTF, whereas spinal p38 MAPK inhibition (SB202190) rescued pLTF at both 24 hours and 1 wk after LPS. These findings suggest that distinct mechanisms underlie pLTF suppression at 24 h versus 1 wk after LPS, although both mechanisms share downstream p38 MAPK signaling. Since mAIH is emerging as a therapeutic modality to improve respiratory and nonrespiratory motor function in people with neurological disorders, targeting p38 MAPK may prevent persistent plasticity suppression in individuals with a history of inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.